Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) FCF Margin (2018 - 2023)

Denali Therapeutics has reported FCF Margin over the past 6 years, most recently at 7694.71% for Q3 2023.

  • Quarterly FCF Margin fell 609289.0% to 7694.71% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 32372.53% through Jun 2024, down 3228403.0% year-over-year, with the annual reading at 112.22% for FY2023, 11475.0% up from the prior year.
  • FCF Margin was 7694.71% for Q3 2023 at Denali Therapeutics, down from 37.73% in the prior quarter.
  • Over five years, FCF Margin peaked at 161.2% in Q4 2020 and troughed at 5024000.0% in Q1 2021.
  • The 5-year median for FCF Margin is 759.48% (2019), against an average of 288611.89%.
  • Year-over-year, FCF Margin crashed -502244113bps in 2021 and then soared 502382862bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 780.52% in 2019, then soared by 121bps to 161.2% in 2020, then tumbled by -440bps to 547.76% in 2021, then crashed by -35bps to 738.43% in 2022, then plummeted by -942bps to 7694.71% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's FCF Margin are 7694.71% (Q3 2023), 37.73% (Q2 2023), and 175.26% (Q1 2023).